Researchers Deform Cells to Deliver RNA, Proteins, and Nanoparticles for Many Applications
|
By LabMedica International staff writers Posted on 06 Feb 2013 |

Image: As cells squeeze through a narrow channel, tiny holes open in their membranes, allowing large molecules such as RNA to pass through (Photo courtesy of Armon Sharei and Emily Jackson).
Researchers have found a safe and effective way to push large molecules through the cell membrane by jamming the cells through a narrow constriction that opens up very small, temporary holes in the membrane. Any large molecules drifting outside the cell—such as proteins, RNA, or nanoparticles—can slide through the membrane during this disruption.
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Living cells are enclosed by a membrane that closely controls what gets in and out of the cell. This barrier is necessary for cells to control their internal environment, but it makes it more difficult for scientists to deliver large molecules such as nanoparticles for imaging, or proteins that can reprogram them into pluripotent stem cells.
Using this technique, the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA: www.mit.edu) researchers were able to deliver reprogramming proteins and create induced pluripotent stem cells with a success rate 10 to 100 times superior than any existing application. They also used it to deliver nanoparticles, including quantum dots and carbon nanotubes, which can be used to image cells and track what is occurring inside them.
“It’s very useful to be able to get large molecules into cells. We thought it might be interesting if you could have a relatively simple system that could deliver many different compounds,” said Dr. Klavs Jensen, a professor of chemical engineering, professor of materials science and engineering, and a senior author of a paper describing the new device in this week’s issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Scientists had earlier developed several approaches to get large molecules into cells, but all of them have downsides. DNA or RNA can be parceled into viruses, which are proficient at entering cells, but that approach carries the risk that some of the viral DNA will be incorporated into the host cell. This application is commonly used in lab experiments but has not been approved by the US Food and Drug and Administration (FDA) for use in human patients.
Another way to transport large molecules into a cell is to tag them with a short protein that can penetrate the cell membrane and tug the larger payload along with it. Alternatively, DNA or proteins can be packaged into synthetic nanoparticles that can enter cells. However, these systems frequently need to be remodified depending on the type of cell and substance being delivered. Moreover, with some nanoparticles, a lot of the material ends up stuck in protective sacs called endosomes inside the cell, and there can be potential toxic side effects.
Electroporation, which involves jolting cells with electricity that opens up the cell membrane, is a more general approach but can be damaging to both cells and the material being delivered.
The new MIT system appears to work for many cell types—up to now, the researchers have successfully tested it with more than a dozen types, including both human and mouse cells. It also works in cells taken directly from human patients, which are typically much more difficult to engineer than human cell lines grown specifically for lab research.
The new device builds on earlier research by Jensen and Langer’s labs, in which they used microinjection to push large molecules into cells as they flowed through a microfluidic device. This was not as fast as the researchers hoped, but during these studies, they discovered that when a cell is squeezed through a narrow tube, small holes open in the cell membrane, allowing neighboring molecules to diffuse into the cell.
To take advantage of that, the researchers built rectangular microfluidic chips, about the size of a quarter, with 40 to 70 parallel channels. Cells are suspended in a solution with the material to be delivered and flowed through the channel at high speed—approximately one meter per second. Halfway through the channel, the cells pass through a constriction about 30%–80% smaller than the cells’ diameter. The cells do not sustain any permanent damage, and they maintain their normal functions after the treatment.
The scientists are now studying stem cell manipulation, which has potential for treating a wide range of diseases. They have already shown that they can convert human fibroblast cells into pluripotent stem cells, and now plan to start working on delivering the proteins needed to differentiate stem cells into specialized tissues.
Another promising application is delivering quantum dots—nanoparticles made of semiconducting metals that fluoresce. These dots hold promise for labeling individual proteins or other molecules inside cells, but scientists have had trouble getting them through the cell membrane without being trapped in endosomes.
In earlier work in November 2012, working with MIT graduate student Jungmin Lee and chemistry professor Dr. Moungi Bawendi, the researchers demonstrated that they could get quantum dots inside human cells grown in the laboratory, without the particles becoming confined in endosomes or clumping together. They are now working on getting the dots to tag specific proteins inside the cells.
The researchers are also exploring the possibility of using the new system for vaccination. In theory, scientists could take immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient. Once inside, the cells could provoke an immune response that would confer immunity against the target viral protein.
Related Links:
Massachusetts Institute of Technology
Latest BioResearch News
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Urine-Based Assay Predicts Severe Dengue Risk Early
Dengue is among the most widespread mosquito-borne infections, yet early risk stratification can be difficult when symptoms overlap with other febrile illnesses. Only about 2% to 5% of patients develop... Read more
CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis
Multiple sclerosis affects more than 2.9 million people worldwide and requires ongoing evaluation of disease activity to guide care. Routine monitoring often depends on magnetic resonance imaging (MRI),... Read more
Ultrasensitive Assay Tracks Resistance Mutations MRD Monitoring
Ultrasensitive circulating tumor DNA assessment is being applied to predict and track response to immunotherapy and to detect relapse across multiple solid tumors. Monitoring resistance mutations such... Read more
Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition whose incidence is rising in industrialized and newly industrialized countries, with prevalence in early‑industrialized... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channel
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read moreAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
Clinicians often struggle to distinguish bacterial from viral infections at first presentation because symptoms overlap and definitive culture or molecular results can take hours or days.... Read more







